Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy.
Transpl Infect Dis
; 15(1): E33-9, 2013 Feb.
Article
en En
| MEDLINE
| ID: mdl-23278987
ABSTRACT
Mycobacterium tuberculosis infection is one of many opportunistic infections in renal transplant recipients, arising either from reactivation of latent infection or de novo infection, occasionally donor derived. M. tuberculosis hepatitis has never been reported in patients who have received alemtuzumab as part of their renal transplant management. We describe 2 patients who underwent deceased-donor renal transplantation following alemtuzumab induction therapy and presented with a febrile syndrome, subsequently diagnosed as tuberculous hepatitis, one with disseminated disease. Both responded well to treatment without significant side effects, resulting in excellent graft function. The importance of chemoprophylaxis should be emphasized to minimize the risk of developing active tuberculosis in patients with latent tuberculosis infection undergoing solid organ transplantation.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Tuberculosis Hepática
/
Infecciones Oportunistas
/
Terapia de Inmunosupresión
/
Trasplante de Riñón
/
Anticuerpos Monoclonales Humanizados
/
Inmunosupresores
/
Antituberculosos
Idioma:
En
Revista:
Transpl Infect Dis
Asunto de la revista:
TRANSPLANTE
Año:
2013
Tipo del documento:
Article